Annual report [Section 13 and 15(d), not S-K Item 405]

General - Schedule of Consolidated Statements of Operations (Details)

v3.25.1
General - Schedule of Consolidated Statements of Operations (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2024
USD ($)
Adaptive Phage Therapeutics LLC [Member]  
Schedule of Consolidated Statements of Operations [Line Items]  
Net loss attributable to APT $ 16,792 [1]
[1] Including impairments loss related to goodwill, IPR&D and long-lived assets of $801, $3,237 and $4,046, respectively.